Adding venetoclax to standard chemo for relapsed AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether adding a drug called venetoclax to the usual chemotherapy (CLAG) helps people whose acute myeloid leukemia (AML) has come back or not responded to treatment. It aims to see if the combination improves outcomes compared to chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 65 years old.
- You have acute myeloid leukemia (AML) that has returned after treatment or has not responded to at least two rounds of standard therapy.
- You are generally able to care for yourself (ECOG score 0-2).
- Your kidneys and liver are working well enough (creatinine clearance at least 30 ml/min, and liver enzymes within certain limits).
- You can take oral medications (venetoclax is a pill).
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding venetoclax (a targeted drug) to standard chemotherapy helps patients with acute myeloid leukemia (a blood cancer) who have responded well to initial treatment stay cancer-free longer. You would receive the combination or standard therapy alone to see which works better.
This trial studies how well venetoclax combined with chemotherapy treats newly diagnosed or returning (relapsed) or hard-to-treat (refractory) acute myeloid leukemia (AML). It’s mainly for people who can’t use standard AML therapy well, or whose disease came back.
This trial studies whether adding venetoclax to standard induction chemotherapy (homoharringtonine plus cytarabine) can improve outcomes for people with newly diagnosed AML. It mainly looks at people who can safely receive intensive chemotherapy but have certain heart, kidney, or lung limits.
This trial tests a combination of targeted therapy (venetoclax) and chemotherapy (cladribine, cytarabine, G-CSF, mitoxantrone) for people with acute myeloid leukemia that has come back or not responded to previous treatment. It aims to see if this combination can help achieve remission.
This trial tests adding venetoclax (a targeted pill) to strong chemotherapy for people with newly diagnosed AML. It is for those whose leukemia cells do not clear quickly enough after standard induction therapy, to see if the combination helps them achieve remission.
This trial tests whether adding the targeted drug venetoclax to intensive chemotherapy works better for different types of AML. It is for people aged 14 to 60 who are newly diagnosed and have not received prior treatment.
Hear when a new Relapsed/Refractory AML trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.